Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06946589
PHASE4

Cardiac Changes After Effective Dose Carbetocin for Elective Caesarian Section

Sponsor: Jordan Leitch

View on ClinicalTrials.gov

Summary

The goal of this project is to examine the cardiac symptoms and physiologic changes after administration of a reduced dose of carbetocin in participants undergoing elective cesarian section. * Does reduced dose carbetocin (50mcg) have fewer cardiac side effects than usual dose carbetocin (100mcg) when comparing patient reported symptoms, ECG changes and troponin increases? * Is there a relationship between patient reported cardiac symptoms after carbetocin administration and subjective measures of cardiac ischemia (ECG changes and troponin increases? Researchers will compare 50mcg of carbetocin to the control group of 100mcg of carbetocin in patients undergoing elective cesarian section. Participants will: * Be given 50mcg or 100mcg of carbetocin during cesarian section * Asked to report cardiac symptoms * Be assessed for ECG changes and blood loss using standard of practice monitoring * Have a troponin I blood test completed after delivery

Key Details

Gender

FEMALE

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

200

Start Date

2025-08-01

Completion Date

2027-09-01

Last Updated

2025-04-27

Healthy Volunteers

No

Interventions

DRUG

Carbetocin

A uterotonic agent used for the prevention of postpartum hemorrhage in Cesarian section

Locations (1)

Kingston Health Sciences Centre

Kingston, Ontario, Canada